Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cobra Biologics’ Growth is Strengthened

Published: Tuesday, October 23, 2012
Last Updated: Tuesday, October 23, 2012
Bookmark and Share
A new non-executive director joins Cobra’s board to support expansion plans.

Cobra Biologics has announced the appointment of a new non-executive director to Cobra Biologics’ board to provide further experience in the CMO sector as Cobra continues to expand with increased capacity and a 40% increase in headcount in the last 12 months.

The appointment of John Birch, former Chief Scientific Officer for Lonza Biopharmaceuticals, as a non-executive director will provide Cobra’s board with unrivalled experience in the CMO sector.

He will provide a wealth of knowledge and experience that will be hugely beneficial to the board and the company overall and will focus Cobra’s efforts to expand the service offering and capabilities.

Biography of the Non-Executive Director:

John Birch (Ph.D.) graduated in microbiology from London University where he also completed a Ph.D. After a period lecturing at the University he moved into industry, holding senior technical positions at Tate and Lyle, G.D. Searle, Celltech and Lonza.

Prior to his retirement he was Chief Scientific Officer, Lonza Biopharmaceuticals. His scientific interests have focused on the production of therapeutic proteins, particularly from mammalian cells and he has published extensively in this field.

In 2005 he was awarded the Donald medal by the I.Chem.E in the UK for contributions to biochemical engineering.

Peter Coleman CEO of Cobra Biologics said “I am extremely pleased that John has decided to join Cobra’s board at a very exciting time for the company and our customers. We have set ourselves ambitious expansion targets for the year and our success has meant rapid recruitment to sustain the increased number of customer projects coming through. The board and I look forward to working with John and our new employees to achieve our ambitious goals.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics Develop Special Cell Line for Alligator Bioscience
The cell line designed expresses monoclonal antibodies that have been vital for the success of a clinical trial ran by Alligator Biosciences.
Thursday, May 28, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics Granted Approval for Research Tax Credit
Company has recognized as an approved service provider for the period 2013 to 2015.
Wednesday, April 02, 2014
Cobra Biologics and BioCancell Announce Agreement
Agreement to manufacture promising cancer therapy drug.
Tuesday, March 04, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Novolytics Develop Bacteriophages Against Infection
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.
Wednesday, June 12, 2013
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
New contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate program.
Tuesday, January 15, 2013
Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
Agreement for the production of monoclonal antibody drug substance and drug product for pre-clinical studies and Phase I-II clinical trials.
Tuesday, June 19, 2012
Cobra Biologics’ Expansion Continues
Appointment of three non-executive directors and two business development managers to Cobra Biologics’ board.
Tuesday, February 14, 2012
Cobra Biologics Acquires Unitech Pharma Group
Acquisition to expand Cobra’s capacity and biopharmaceutical service offering.
Tuesday, November 01, 2011
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!